712. Identification of a novel tedizolid resistance mutation in rpoB of methicillin-resistant Staphylococcus aureus
Session: Poster Abstract Session: Resistance Mechanisms: Gram-Positive
Thursday, October 4, 2018
Room: S Poster Hall
Posters
  • IDWEEK_2018_poster.pdf (1.7 MB)
  • Background:

    Tedizolid (TDZ) is an oxazolidinone antimicrobial with broad spectrum activity against Gram positive bacteria including methicillin-resistant S. aureus (MRSA). Resistance to TDZ is uncommon but mutations in the 23S rRNA target as well as in the transferable rRNA methyltransferase gene cfr, which also mediate resistance to linezolid and chloramphenicol have been implicated. The objective of the present study was to determine if other TDZ resistance pathways exist in MRSA.

    Methods:

    Using a well characterized MRSA strain, N315, we selected for TDZ resistance by serial passage in escalating concentrations of TDZ in Mueller Hinton broth (MHB) starting with 0.5x the MIC. Once visible growth was achieved a sample of the broth was diluted 1:1000 into fresh MHB with twice the previous concentration of TDZ until an isolate with an MIC of >=4 mg/mL was recovered. This MIC was selected since it is 1 dilution above the breakpoint for resistance >=2mg/L). This isolate was subjected to whole genome sequencing (WGS) and MICs to other antimicrobials were assessed. Homology modeling was performed to evaluate the potential impact of the mutation on target protein function.

    Results:

    After 10 days of serial passage we recovered a stable mutant with a TDZ MIC of 4 mg/L. WGS revealed a single nucleotide variant (A1345G) in the rpoB gene corresponding to an amino acid substitution at D449N. The following table and figure summarize the changes in drug susceptibility between the parent and evolved strain and reveals the location of the amino acid substitution relative to the TDZ binding site.

     

     

    MIC (mg/L)

     

    Drug

    N315

    N315-TDZ4

    Chloramphenicol

    8

    128

    Doxycycline

    0.125

    0.125

    Linezolid

    2

    8

    Moxifloxacin

    0.0625

    0.0625

    Rifampin

    0.001

    0.001

    Tedizolid

    0.25

    4

    Vancomycin

    0.5

    1

     

     

     

    Conclusion:

    We have identified a novel mutation in the RNA polymerase gene, rpoB, that mediates oxazolidinone and chloramphenicol resistance. This variant lies outside of the rifampin resistance determinant clusters of rpoB that span from 1384 - 1464 and 1543 - 1590, and as expected did not affect rifampin susceptibility. The underlying molecular mechanism by which this single nucleotide variant confers TDZ resistance remains unclear but may involve transcriptional modulation by altered sigma factor binding.

    Brian Werth, PharmD1, Kelsi Penewit, MS2, Stephen Salipante, MD, PhD2, Tianwei Shen, MS3, Libin Xu, PhD3 and Abhinav Nath, PhD3, (1)Department of Pharmacy, University of Washington School of Pharmacy, Seattle (Washington), WA, (2)Department of Laboratory Medicine, University of Washington School of Medicine, Seattle (Washington), WA, (3)Department of Medicinal Chemistry, University of Washington School of Pharmacy, Seattle (Washington), WA

    Disclosures:

    B. Werth, None

    K. Penewit, None

    S. Salipante, None

    T. Shen, None

    L. Xu, None

    A. Nath, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.